Evidence of clinical utility:An unmet need in molecular diagnostics for patients with cancer

Abstract

This article defines and describes best practices for the academic and business community to generate evidence of clinical utility for cancer molecular diagnostic assays. Beyond analytical and clinical validation, successful demonstration of clinical utility involves developing sufficient evidence to demonstrate that a diagnostic test results in an improvement in patient outcomes.This discussionis complementary to theoretical frameworks described in previously published guidance and literature reports by the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, Institute of Medicine, and Center for Medical Technology Policy,among others. These reports are comprehensive and specifically clarify appropriate clinical use, adoption, and payer reimbursement for assaymanufacturers, as well as Clinical Laboratory Improvement Amendments certified laboratories, including those that develop assays (laboratory developed tests). Practical criteria and steps for establishing clinical utility are crucial to subsequent decisions for reimbursement without which high-performing molecular diagnostics will have limited availability to patients with cancer and fail to translate scientific advances into high-quality and cost-effective cancer care. © 2014 American Association for Cancer Research.